Phase I clinical study of paroxetine HCl (Study 3): Pharmacokinetics after single oral administration of paroxetine HCl 10, 20 and 40 mg to healthy adult male volunteers

Japanese Pharmacology and Therapeutics

Volumn 28, Issue SUPPL. 1, 2000, Pages

  Irie, H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; DEPRESSION; DRUG INDICATION; DRUG RESEARCH; DRUG SCREENING; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; VOLUNTEER;

EID: 0033831642     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Interaction between a selective 5-HT(1A) receptor antagonist and an SSRI in vivo; Effects on 5-HT cell firing and extracellular 5-HT
2. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor
3. Comparison of some effects of paroxetine with amitriptyline on the cardiovascular system in animals
4. Cardiovascular effects of paroxetine, a newly developed antidepressant, in anesthetized dogs in comparison with those of imipramine, amitriptyline and clomipramine
5. A double-blind multicentre study of paroxetine and amitriptyline in depressed outpatients
6. A study comparing paroxetine placebo and imipramine in depressed patients
7. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients
8. Long-term treatment and prevention of relapse of obsessive compulsive disorder with paroxetine
9. Paroxetine efficacy in social phobia
10. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism
11. A review of the metabolism and pharmacokinetics of paroxetine in man
12. The relationship between paroxetine and the sparteine oxidation polymorphism
13. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine
14. Paroxetine plasma levels: Lack of correlation with effficacy or adverse events
15. 14C-BRL29060A equivalent to 30 mg pure free base
16. Neurochemical assessment of acute and chronic paroxetine treatment on monoamine neurotransmitters and metabolites in the rat brain
17. Paroxetine: Post-marketing experience on 4024 depressed patients in Belgium